HomeNewsTrendsHealthCOVID-19 cases on upswing, JN.1 subvariant in focus; what we know so far

COVID-19 cases on upswing, JN.1 subvariant in focus; what we know so far

There are currently 2,311 active COVID-19 cases in India, as per the health ministry data. So far, 21 cases linked to the contagious JN.1 subvariant have been detected.

December 20, 2023 / 22:54 IST
Story continues below Advertisement
The maximum number of JN.1 cases have been recorded in Kerala so far
The maximum number of JN.1 cases have been recorded in Kerala so far

An uptick in the number of coronavirus cases across the country has spread concern, with the number of daily infections rising to a seven-month high.

A total of 614 cases were recorded across the country in the last 24 hours, the health ministry said on December 20, which marks a significant jump as compared to 115 cases registered on December 6. This was also the highest number of daily infections recorded since May 21.

Story continues below Advertisement

The upswing in infections has drawn focus towards JN.1 subvariant of COVID-19, which comes through the lineage of the Omicron variant that was blamed for a surge in infections in 2021-end.

NITI Aayog member (Health) Dr V K Paul confirmed that the focus is on JN.1, even as only 21 coronavirus infections so far in India have been linked to the variant.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show